Here Are the 10 Medicare Negotiated Drug Prices
These prices come from the first set of negotiations between Medicare and drug companies.
After many months of closely watched negotiations, the Centers for Medicare & Medicaid Services (CMS) announced the list of negotiated prices for 10 drugs. This marks the first set of negotiations between Medicare and drug makers taking place as part of the Inflation Reduction Act, which President Joe Biden signed into law in 2022.
"Americans pay too much for their prescription drugs. That makes today’s announcement historic,” Department of Health and Human Services (HHS) Secretary Xavier Becerra said in a CMS press release.
The 10 drugs Medicare negotiated prices for include blockbusters Jardiance, Stelara and Eliquis. The drugs treat diabetes, heart failure, arthritis and more, and the negotiated prices are as much as 79% lower than their prices in 2023. The negotiated prices apply for people with Medicare Part D prescription drug coverage.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Biden White House said the negotiated prices will save taxpayers an estimated $6 billion, and people enrolled in Medicare with Part D prescription drug coverage are expected to save $1.5 billion in out-of-pocket costs. The Congressional Budget Office estimates Medicare will save $100 billion over the next 10 years thanks to these negotiations.
The list of Medicare negotiated drug prices
Medicare announced the 10 drugs it chose to negotiate prices for last year. Those drugs were Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog.
CMS is following a certain set of parameters to determine which drugs are eligible for negotiations, which includes when the drugs were approved by the FDA and what they treat. After narrowing down a list of drugs eligible for negotiation under the parameters, Medicare further narrowed down the list to these 10 drugs based on which had the highest Medicare Part D expenditures.
These are the negotiated prices, noting that each price is for a 30-day supply:
Eliquis:
- Drug description: Eliquis is a blood thinner used to treat and prevent blood clots. It is commonly prescribed to people who have atrial fibrillation, deep vein thrombosis and pulmonary embolism, and people who have recently had hip or knee replacement surgery and thus are at higher risk of blood clots
- Negotiated price: $231
- Price in 2023: $521
- Price reduction: 56%
Jardiance
- Drug description: Jardiance is commonly prescribed to people with Type 2 diabetes, heart failure and chronic kidney disease. It it used to reduce the risk of cardiovascular death for those patients; reduce the worsening of kidney disease; and lower blood sugar for Type 2 diabetics, along with diet and exercise
- Negotiated price: $197
- Price in 2023: $573
- Price reduction: 66%
Xarelto
- Drug description: Xarelto is also, like Eliquis, used for the prevention and treatment of blood clots, as well as to reduce the risk of serious heart problems, along with low-dose aspirin
- Negotiated price: $197
- Price in 2023: $517
- Price reduction: 62%
Januvia
- Drug description: Januvia is prescribed to people with Type 2 diabetes to help lower blood sugar levels, along with diet and exercise
- Negotiated price: $113
- Price in 2023: $527
- Price reduction: 79% - this is the largest price reduction of these negotiations by percentage
Farxiga
- Drug description: Farxiga, like Jardiance, is prescribed to patients with Type 2 diabetes, heart failure and chronic kidney disease.
- Negotiated price: $178.50
- Price in 2023: $556
- Price reduction: 68%
Entresto
- Drug description: Entresto is prescribed to people with long-lasting or chronic heart failure
- Negotiated price: $295
- Price in 2023: $628
- Price reduction: 53%
Enbrel
- Drug description: Enbrel is prescribed to treat arthritis, psoriasis, and psoriatic arthritis. It is supposed to reduce joint pain and stop permanent joint damage
- Negotiated price: $2,355
- Price in 2023: $7,106
- Price reduction: 67%
Imbruvica
- Drug description: Imbruvica is used to treat blood cancers, including chronic lymphocytic leukemia, Waldenström's macroglobulinemia and chronic graft versus host disease (cGVHD). It is not a chemotherapy drug
- Negotiated price: $9,319
- Price in 2023: $14,934
- Price reduction: 38%
Stelara
- Drug description: Stelara is prescribed to people with Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. It is used via an IV infusion followed by a set of injections over several weeks
- Negotiated price: $4,695
- Price in 2023: $13,836
- Price reduction: 66%
Fiasp/NovoLog
- Drug description: This negotiation includes Fiasp, Fiasp FlexTouch, Fiasp PenFill, NovoLog, NovoLog FlexPen and NovoLog PenFill. These are insulin injections used to treat diabetes
- Negotiated price: $119
- Price in 2023: $495
- Price reduction: 76%
When do the Medicare drug prices go into effect?
These negotiated drug prices will go into effect for Medicare Part D recipients on Jan. 1, 2026. Approximately 10 million Medicare enrollees used this set of 10 drugs in 2023 (combined), so it's expected the lower prices will have a wide impact.
Along with these drug prices, Part D recipients will soon see other changes in prices. Starting in 2025, they will have a $2,000 cap on out-of-pocket costs, also as part of the Inflation Reduction Act. This is one of the Medicare changes coming in 2025, and the cap could change after 2025.
What's next for Medicare drug price negotiations?
This marks just the first set of Medicare drug price negotiations. Next year, Medicare will select up to 15 more drugs to negotiate for Part D recipients. The following year, 2026, Medicare will select another up to 15 drugs to negotiate, and that will be for drugs covered under Part D or Part B.
The plan is for Medicare to continue to negotiate up to 20 drugs every year after 2026.
"We applaud this monumental milestone in curbing rising drug prices and helping older adults afford their medications while reducing costs for taxpayers," the Medicare Rights Center said about the announcement of the first set of negotiated prices. "The effect of these negotiations will build upon itself year after year as more and more drugs have prices that better reflect their value."
Related Content
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Alexandra Svokos is the senior digital editor of Kiplinger. She holds an MBA from NYU Stern in finance and management and a BA in economics and creative writing from Columbia University. Alexandra has a decade of experience in journalism and previously served as the senior editor of digital for ABC News, where she directed daily news coverage across topics through major events of the early 2020s for the network's website, including stock market trends, the remote and return-to-work revolutions, and the national economy. Before that, she pioneered politics and election coverage for Elite Daily and went on to serve as the senior news editor for that group.
Alexandra was recognized with an "Up & Comer" award at the 2018 Folio: Top Women in Media awards, and she was asked twice by the Nieman Journalism Lab to contribute to their annual journalism predictions feature. She has also been asked to speak on panels and give presentations on the future of media and on business and media, including by the Center for Communication and Twipe.
-
Retirement Abroad? Three Countries With No Inheritance Tax
Retirement Taxes These 2025 top-retiree-friendly countries have an added benefit: potential tax savings for you and your heirs.
By Kate Schubel
-
Five Tax-Savvy Ways To Donate This Holiday Season
Charitable Donations Food pantries, toy drives, and animal sanctuaries are popular ways to support others year-round.
By Gabriella Cruz-Martínez Published
-
A Checklist for Retiring in 2025
Navigating the final stretch of your professional career can be daunting. We've compiled a checklist to help you put your best foot forward into retirement.
By Alina Tugend Published
-
I Won’t Be Handing Out Gift Cards This Christmas. Here’s Why
Gift cards are usually considered a safe bet at Christmas, but in these strained times, how can you be sure your gift won't go to waste?
By Charlotte Gorbold Published
-
Three Possible Tax Impacts for Retirees Under Trump
How might a second Trump term affect your tax bill in retirement — or the inheritance tax bill for your heirs? This pro has three predictions.
By Evan T. Beach, CFP®, AWMA® Published
-
What to Know About Leverage and Bitcoin's Meteoric Rise
Leverage in the financial world can lead to astonishing success or a crushing collapse. How are investors using leverage to invest in bitcoin?
By Stephen P. Harbeck Published
-
How Do You Know When It's Time to Change Financial Advisers?
Sometimes a breakup is for the best. Here's how to handle 'the talk' and make the switch to a new professional who's a better fit for you.
By Kelli Kiemle, AIF® Published
-
Quicken Launches New Tool to Protect Your Financial Documents: Is it Worth it?
If you're looking for a secure place to store your financial documents, Quicken's LifeHub offers you an easy and affordable way to do so.
By Sean Jackson Published
-
CPI Report Casts Doubt on Rate Cuts in 2025: What the Experts Are Saying About Inflation
CPI November Consumer Price Index data sealed the deal for a December rate cut, but the outlook for next year is less certain.
By Dan Burrows Published
-
Quiz: Test Your Financial Literacy
Try your hand at these three questions designed to gauge your knowledge of the ABCs of personal finance. In a survey, only 43% of Americans answered correctly.
By Janet Bodnar Published